Ake­bia ex­pects to file vadadu­s­tat again to FDA by end of Q3; So­ci­etal CD­MO seeks to se­cure 8M+ in lat­est raise

Ake­bia now ex­pects to re­file its chron­ic kid­ney dis­ease treat­ment vadadu­s­tat by the end of Sep­tem­ber.

The biotech said Thurs­day morn­ing that it had a Type A meet­ing with reg­u­la­tors last month.

The FDA re­ject­ed the com­pa­ny’s lead can­di­date for pa­tients with ane­mia due to chron­ic kid­ney dis­ease back in March 2022 over safe­ty con­cerns, and in May, Ake­bia said it would re­file some­time in the sec­ond half of 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER